BIO-Europe 2019

BIO-Europe 2019 November 11–13, 2019 / Hamburg / Germany Laurence de Schoulepnikoff attending

AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091

Geneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]

Amal Therapeutics to publish R&D outcomes in JCI Insight

Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens),  its […]

AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF  

CICON 2019

CICON 2019 Sept. 25 – 28, 2019 / Paris / France Elodie Belnoue attending

BIO International Convention 2019

BIO International Convention 2019 June 3 – 6, 2019 / Philadelphia / USA Madiha Derouazi and Laurence de Schoulepnikoff attending

CIMT Annual Meeting 2019

CIMT Annual Meeting 2019 May 21 – 23, 2019 / Mainz / Germany Matteo Rossi attending

Swiss Biotech Day 2019

Swiss Biotech Day 2019 May 7, 2019 / Basel / Switzerland Laurence de Schoulepnikoff attending